Arca biopharma announces 2023 financial results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options westminster, colo., feb. 01, 2024 (globe newswire) -- arca biopharma, inc. (nasdaq: abio), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2023 financial results and provided a corporate update.
ABIO Ratings Summary
ABIO Quant Ranking